Trends in Thoracic Impedance and Arrhythmia Burden Among Patients with Implanted Cardiac Defibrillators During the COVID-19 Pandemic

Lu, Yuan; Murugiah, Karthik; Jones, Paul; Caraballo, César; Mahajan, Shiwani; Massey, Daisy; Ahmed, Rayaz; Bader, Eric; Krumholz, Harlan M.

doi:10.1101/2021.02.27.21252559

Cited by 3 publications

(3 citation statements)

References 3 publications

(2 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We present evidence that the observed sensor changes are in some way associated with COVID-19 infection because the magnitude of change was significantly different for COVID-positive versus negative and control patients. For instance, although activity significantly decreased among all patient cohorts, likely due to stay-at-home orders limiting activity for all New York City residents as observed in prior studies, 14 we observed a significantly greater decrease in activity for COVID-positive patients. Similarly, we observed distinctly different sensor changes between COVID-positive and COVID-negative patients.…”

Section: Discussionsupporting

confidence: 65%

Detecting early physiologic changes through cardiac implantable electronic device data among patients with COVID-19

Turchioe

Ahmed

Creber

et al. 2022

Cardiovascular Digital Health Journal

Self Cite

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 65%

Detecting early physiologic changes through cardiac implantable electronic device data among patients with COVID-19

Turchioe

Ahmed

Creber

et al. 2022

Cardiovascular Digital Health Journal

Self Cite

View full text Add to dashboard Cite

“…stitial fluid status in pulmonary oedema [224,225] and have been suggested to be a possible marker of disease severity in a very small sample of COVID-19 patients [223]. These preliminary findings deserve larger scale validation.…”

Section: Fig 4 Summary Of Documented Abnormalities On Electrocardiogr...mentioning

confidence: 83%

“…Implantable cardiac defibrillators can assess thoracic impedance by measuring the resistance between the right ventricular lead and the device, traversing significant volumes of lung tissue [223]. Changes in thoracic impedance reflect the interstitial fluid status in pulmonary oedema [224, 225] and have been suggested to be a possible marker of disease severity in a very small sample of COVID‐19 patients [223]. These preliminary findings deserve larger scale validation.…”

Section: Markers Of Pulmonary Dysfunctionmentioning

confidence: 99%

Effective prognostic and clinical risk stratification in COVID‐19 using multimodality biomarkers

et al. 2023

View full text Add to dashboard Cite

In acute coronavirus disease 19 (COVID‐19) patients, effective clinical risk stratification has important implications on treatment and therapeutic resource distribution. This article reviews the evidence behind a wide range of biomarkers with prognostic value in COVID‐19. Patient characteristics and co‐morbidities, such as cardiovascular and respiratory diseases, are associated with increased mortality risk. Peripheral oxygen saturation and arterial oxygenation are predictive of severe respiratory compromise, whereas risk scores such as the 4C‐score enable multi‐factorial prognostic risk estimation. Blood tests such as markers of inflammation, cardiac injury and d‐dimer and abnormalities on electrocardiogram are linked to inpatient prognosis. Of the imaging modalities, lung ultrasound and echocardiography enable the bedside assessment of prognostic abnormalities in COVID‐19. Chest radiograph (CXR) and computed tomography (CT) can inform about prognostic pulmonary pathologies, whereas cardiovascular CT detects high‐risk features such as coronary artery and aortic calcification. Dynamic changes in biomarkers, such as blood tests, CXR, CT and electrocardiogram findings, can further inform about disease severity and prognosis. Despite the vast volumes of existing evidence, several gaps exist in our understanding of COVID‐19 biomarkers. First, the pathophysiological basis on which these markers can foretell prognosis in COVID‐19 remains poorly understood. Second, certain under‐explored tests such as thoracic impedance assessment and cardiovascular magnetic resonance imaging deserve further investigation. Lastly, the prognostic values of most biomarkers in COVID‐19 are derived from retrospective analyses. Prospective studies are required to validate these markers for guiding clinical decision‐making and to facilitate their translation into clinical management pathways.

show abstract

Long COVID prevalence and impact on quality of life 2 years after acute COVID-19

Kim

Bae

Chang

et al. 2023

Sci Rep

View full text Add to dashboard Cite

There has been an increasing interest in the long-term impact of long COVID. However, only a few studies have investigated the clinical manifestations of long COVID after 24 months of acute infection. In this study, prospective online surveys were conducted in adults previously diagnosed with coronavirus disease 2019 (COVID-19) in South Korea between February 13 and March 13, 2020, at 6, 12, and 24 months after COVID-19. We investigated self-reported symptoms and the EuroQol-5-dimension index. Among 900 individuals enrolled initially, 150 completed all 3 surveys. After excluding the cases of COVID-19 reinfection, 132 individuals were included in the final analysis. Among the 132 participants, 94 (71.2%) experienced symptoms of long COVID. The most frequently reported symptoms were fatigue (34.8%), amnesia (30.3%), concentration difficulties (24.2%), insomnia (20.5%), and depression (19.7%). Notably, no significant differences were noted in the incidence of long COVID at 24 months in terms of the number of vaccinations received. Although the neuropsychiatric quality of life improved over time, it continued to affect 32.7% of participants. Symptoms of long COVID, particularly neuropsychiatric symptoms, tend to persist over time, and COVID-19 vaccination or the number of vaccinations received may not significantly affect the incidence of long COVID.

show abstract

Trends in Thoracic Impedance and Arrhythmia Burden Among Patients with Implanted Cardiac Defibrillators During the COVID-19 Pandemic

Cited by 3 publications

References 3 publications

Detecting early physiologic changes through cardiac implantable electronic device data among patients with COVID-19

Detecting early physiologic changes through cardiac implantable electronic device data among patients with COVID-19

Effective prognostic and clinical risk stratification in COVID‐19 using multimodality biomarkers

Long COVID prevalence and impact on quality of life 2 years after acute COVID-19

Contact Info

Product

Resources

About